The Progression and Regression of Metabolic Dysfunction-associated Fatty Liver Disease are Associated with the Development of Subclinical Atherosclerosis: A Prospective Analysis

Metabolic dysfunction-associated fatty liver disease (MAFLD) has been proposed and diagnosed based on modified criteria. However, evidence for the risks of developing subclinical atherosclerosis with MAFLD transitions according to its new definition has never been reported.

Source: Metabolism - Clinical and Experimental - April 22, 2021 Category: Biomedical Science Authors: Shanshan Liu, Jialu Wang, Shujing Wu, Jingya Niu, Ruizhi Zheng, Lizhan Bie, Zhuojun Xin, Shuangyuan Wang, Hong Lin, Zhiyun Zhao, Tiange Wang, Min Xu, Jieli Lu, Yuhong Chen, Yiping Xu, Weiqing Wang, Guang Ning, Yufang Bi, Mian Li, Yu Xu Tags: Declaration of interest: none. Source Type: research